Elite Pharmaceuticals Inc represents values of innovation, integrity, and excellence in the pharmaceutical industry. The company is committed to developing and commercializing high-quality generic and niche products that meet the needs of patients, healthcare providers, and stakeholders. By focusing on research, development, and manufacturing, Elite Pharmaceuticals Inc ensures the delivery of safe, effective, and affordable medications. With a customer-centric approach, the company strives to improve health outcomes and enhance the overall quality of life. As a leader in the pharmaceutical market, Elite Pharmaceuticals Inc maintains a strong corporate philosophy centered around continuous improvement, ethical behavior, and responsible business practices.

Elite Pharmaceuticals Inc is primarily present in the United States.

Elite Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and commercialized various generic and niche pharmaceutical products. Elite Pharmaceuticals Inc also forged strategic partnerships with other industry leaders, enabling them to expand their market presence and increase their product offerings. The company has consistently demonstrated its commitment to research and development, resulting in the approval of numerous abbreviated new drug applications (ANDAs) by the FDA. Elite Pharmaceuticals Inc's dedication to innovation and high-quality products has positioned them as a trusted and valuable player in the pharmaceutical industry.

Elite Pharmaceuticals Inc. is a reputable company that has a rich history and background in the pharmaceutical industry. Established in (insert year), Elite Pharmaceuticals Inc. has become a leading player in the field. The company is known for its commitment to innovation and excellence in drug development, manufacturing, and delivery. With a strong focus on research and development, Elite Pharmaceuticals Inc. has successfully developed a diverse portfolio of high-quality and affordable medications. The company's dedication to ensuring the well-being and health of patients has positioned it as a trusted provider in the industry.

The main competitors of Elite Pharmaceuticals Inc in the market include companies such as Teva Pharmaceutical Industries Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, Novartis AG, and Johnson & Johnson.

Elite Pharmaceuticals Inc is primarily active in the pharmaceutical industry and specializes in the development, manufacturing, and commercialization of generic and branded pharmaceutical products.

The business model of Elite Pharmaceuticals Inc is focused on developing and commercializing generic and specialty pharmaceutical products. They strive to improve the accessibility and affordability of medications through their innovative formulations and manufacturing capabilities. Elite Pharmaceuticals Inc aims to address unmet medical needs by creating high-quality, cost-effective drug solutions. Their expertise lies in research and development, regulatory affairs, and product commercialization. By consistently delivering superior products and leveraging strategic partnerships, Elite Pharmaceuticals Inc maintains a strong position in the pharmaceutical industry.

The Elite Pharmaceuticals P/E ratio is 28.57.

The Elite Pharmaceuticals P/S ratio is 10.15.

The Quality Investing for Elite Pharmaceuticals is 5/10.

The Elite Pharmaceuticals revenue is 56.63 M USD.

The Elite Pharmaceuticals profit is 20.11 M USD.

Elite Pharmaceuticals Inc is an American pharmaceutical company that focuses on the manufacturing, marketing, and development of generics. The company was founded in 1984 by an experienced team of pharmaceutical experts to produce cost-effective and affordable generics. In recent years, Elite Pharmaceuticals Inc has established itself as a key player in the pharmaceutical industry. The company's business model is based on the production and marketing of FDA-approved generics. It has a wide range of products that cover various therapeutic classes such as pain management, muscle relaxants, and psychopharmaceuticals. The company utilizes its proprietary technology called Bioral®, which specializes in the production of oral controlled-release systems and ensures improved bioavailability of active ingredients. Elite Pharmaceuticals Inc operates different business segments to ensure the success of the company. The main business segment is the production and marketing of generics, which form the backbone of the company. The company develops and produces generics in its own facilities in the United States, which adhere to the highest safety and quality standards. Another important business segment of Elite Pharmaceuticals Inc is the research and development of new technologies. The company actively pursues new technologies to enhance the effectiveness of its products and strengthen its position as a key player in the pharmaceutical industry. Elite Pharmaceuticals Inc has partnerships with universities and other companies to further enhance its expertise. As part of the generic manufacturing process, Elite Pharmaceuticals Inc works closely with its distribution partners to place its products in the market. The company has an extensive network of distribution partners that distribute its products in various parts of the United States and beyond. Elite Pharmaceuticals Inc is a continuously growing company committed to providing its customers with high-quality and cost-effective generics. The company constantly strives to expand its product range and develop new technologies to maintain its competitive advantage. Overall, the business model of Elite Pharmaceuticals Inc offers an effective combination of research and development, production and marketing of generics, as well as significant partnerships with pharma-focused companies. The products of Elite Pharmaceuticals Inc have already gained a significant position in the pharmaceutical industry, and the company is well positioned to continue growing and expanding in the future.

Elite Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

The dividend cannot currently be calculated for Elite Pharmaceuticals or the company does not pay out a dividend.

The ISIN of Elite Pharmaceuticals is US28659T2006.

The WKN of Elite Pharmaceuticals is 634826.

The ticker of Elite Pharmaceuticals is ELTP.

Over the past 12 months, Elite Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Elite Pharmaceuticals is expected to pay a dividend of 0 USD.

The current dividend yield of Elite Pharmaceuticals is .

Elite Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

Elite Pharmaceuticals paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

Elite Pharmaceuticals is assigned to the 'Health' sector.

To receive the latest dividend of Elite Pharmaceuticals from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

The last dividend was paid out on 11/19/2024.

In the year 2023, Elite Pharmaceuticals distributed 0 USD as dividends.

The dividends of Elite Pharmaceuticals are distributed in USD.